Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Vistra Corp (VST) Price & Performance

Kymera Therapeutics Inc. Common StockTrade
Vistra CorpTrade

Price performance (Past 24H)

Key statistics

Kymera Therapeutics Inc. Common Stock vs Vistra Corp — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Vistra Corp trades at $147.2 (market cap $54.49B). The key difference: Vistra Corp is far larger — about 6.1× Kymera Therapeutics Inc. Common Stock's market cap, and Vistra Corp pays a 0.57% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Vistra Corp for 33 Days on average.

KYMRVST
Market Cap
$8.87B$54.49B
Volume
779,1075,289,982
Sector
HealthUtilities
52-Week High
$127.31$210.85
52-Week Low
$55.80$134.71
Typical Hold Time
0 Days33 Days
Enterprise Value
$8.26B$76.43B
Dividend Yield
—0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kymera Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Vistra Corp

Vistra Corp (VST) trades at $162.36, up 2.68% with strong institutional support and bullish technical indicators. The stock shows impressive profitability with 75.73% ROE and 11.55% net margin, though recent earnings were mixed with Q1 beat but Q2 miss. Recent developments include a $4.2 billion government loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.

Vistra presents significant upside potential with a $215.23 consensus price target (32.5% upside) and 91.3% buy ratings. The company benefits from nuclear power expansion and AI infrastructure demand, though risks include execution of growth initiatives and energy market volatility. Current valuation at 27.38 P/E appears reasonable given growth prospects in the power generation sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KYMR
100% Buy0% Sell
Avg holding period · 0 Days
VST
33% Buy67% Sell
Avg holding period · 33 Days

Top news

Latest headlines on both assets

About Kymera Therapeutics Inc. Common Stock

Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.

Read more on KYMR →

About Vistra Corp

Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.

Read more on VST →